Nanomaterials News

RSS

Thin-Film Silicon Brings Unique Set of Advantages as a Material for Photovoltaics Market

Research and Markets, leading source for international market research and market data, has announced the addition of the "Materials for Thin-Film Silicon Photovoltaics" report to their offering.

From Research and Markets 27 May 2009

Consumer Goods Market Beginning to Exploit the Potential of Nanotechnology

Research and Markets, leading source for international market research and market data, has announced the addition of "nanotechnology in consumer goods" report to their offering. The potential impact of nan...

26 May 2009

Aphios to Present Results of Phase II/III Clinical Trial of Zindol for Cancer Chemotherapy Induced Nausea

Aphios Corporation, a biotechnology company that is developing enabling technology platforms including nanotechnology drug delivery platforms such as phospholipid nanosomes, biodegradable polymer nanospheres, and protein...

26 May 2009

Funding Supports Establishment of Dedicated Nanotechnology Laboratory

The PPG Industries Foundation, a global supplier of paints, coatings, optical products, specialty materials, chemicals, glass and fiber glass, has pledged $500,000 to the Department of Chemistry at the University of Pittsburgh for a laboratory focused on the rapidly developing field of nanoscience.

26 May 2009

Sandia National Laboratories Signs Agreement to Conduct and Share Research of Mutual Interest

Sandia National Laboratories and Japan's National Institute of Advanced Industrial Science and Technology have signed an agreement to conduct and share research of mutual interest. Areas of immediate importance na...

From Sandia National Laboratories 26 May 2009

QD Soleil Signs Exclusive License Agreement for Patents Covering the Work of Nanotechnology Pioneer

QD Soleil™, a division of Nanosys Inc. focused on the use of proprietary nanotechnology in solar panel cell designs, today announced the signing of an exclusive license agreement with Starfire Electronic Developmen...

26 May 2009

NanoViricides Signs Pre-Clinical Study Agreement for the Evaluation of FluCide

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), development stage company that is creating special purpose nanomaterials for viral therapy, announced today that it has signed a pre-clinical study agreement for the evaluation of FluCide™, NanoViricides' universal anti-influenza drug candidate.

From NanoViricides, Inc 26 May 2009